Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice.
Identifieur interne : 001374 ( PubMed/Checkpoint ); précédent : 001373; suivant : 001375Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice.
Auteurs : A. Boireau [France] ; F. Bordier ; P. Dubédat ; C. Pény ; A. ImpératoSource :
- Neuroscience letters [ 0304-3940 ] ; 1997.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 3,4-Dihydroxyphenylacetic Acid (metabolism), Animals, Anti-Inflammatory Agents (pharmacology), Corpus Striatum (drug effects), Corpus Striatum (metabolism), Disease Models, Animal, Dopamine (metabolism), Dose-Response Relationship, Drug, Homovanillic Acid (metabolism), Hypnotics and Sedatives (pharmacology), Immunosuppressive Agents (pharmacology), Male, Mice, Mice, Inbred C57BL, Parkinson Disease (metabolism), Thalidomide (pharmacology).
- MESH :
- chemical , metabolism : 3,4-Dihydroxyphenylacetic Acid, Dopamine, Homovanillic Acid.
- chemical , pharmacology : Anti-Inflammatory Agents, Hypnotics and Sedatives, Immunosuppressive Agents, Thalidomide.
- chemical : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
- drug effects : Corpus Striatum.
- metabolism : Corpus Striatum, Parkinson Disease.
- Animals, Disease Models, Animal, Dose-Response Relationship, Drug, Male, Mice, Mice, Inbred C57BL.
Abstract
The effects of thalidomide, a sedative, anti-inflammatory and immunosuppressive agent were studied in the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) murine model of Parkinson's disease. The striatal levels of dopamine (DA) and of its main metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were measured both in the MPTP control group (3 x 15 mg/kg intraperitoneally) and in the thalidomide groups (repeated treatments at 25 mg/kg or 50 mg/kg postoperatively). For mice treated with thalidomide, a dose-dependent protection was observed against the MPTP-induced decrease in DA. The decrease in HVA levels was totally antagonized by thalidomide at both doses. That thalidomide has activity in this model suggests that an inflammatory process may be involved in the induction of lesions by MPTP in DAergic neurons.
PubMed: 9364513
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:9364513Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice.</title><author><name sortKey="Boireau, A" sort="Boireau, A" uniqKey="Boireau A" first="A" last="Boireau">A. Boireau</name><affiliation wicri:level="1"><nlm:affiliation>Rhône-Poulenc Rorer S.A., Centre de Recherche de Vitry-Alfortville, Vitry-sur-Seine, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Rhône-Poulenc Rorer S.A., Centre de Recherche de Vitry-Alfortville, Vitry-sur-Seine</wicri:regionArea><wicri:noRegion>Vitry-sur-Seine</wicri:noRegion><wicri:noRegion>Vitry-sur-Seine</wicri:noRegion></affiliation></author><author><name sortKey="Bordier, F" sort="Bordier, F" uniqKey="Bordier F" first="F" last="Bordier">F. Bordier</name></author><author><name sortKey="Dubedat, P" sort="Dubedat, P" uniqKey="Dubedat P" first="P" last="Dubédat">P. Dubédat</name></author><author><name sortKey="Peny, C" sort="Peny, C" uniqKey="Peny C" first="C" last="Pény">C. Pény</name></author><author><name sortKey="Imperato, A" sort="Imperato, A" uniqKey="Imperato A" first="A" last="Impérato">A. Impérato</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1997">1997</date><idno type="RBID">pubmed:9364513</idno><idno type="pmid">9364513</idno><idno type="wicri:Area/PubMed/Corpus">001511</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001511</idno><idno type="wicri:Area/PubMed/Curation">001470</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001470</idno><idno type="wicri:Area/PubMed/Checkpoint">001470</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001470</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice.</title><author><name sortKey="Boireau, A" sort="Boireau, A" uniqKey="Boireau A" first="A" last="Boireau">A. Boireau</name><affiliation wicri:level="1"><nlm:affiliation>Rhône-Poulenc Rorer S.A., Centre de Recherche de Vitry-Alfortville, Vitry-sur-Seine, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Rhône-Poulenc Rorer S.A., Centre de Recherche de Vitry-Alfortville, Vitry-sur-Seine</wicri:regionArea><wicri:noRegion>Vitry-sur-Seine</wicri:noRegion><wicri:noRegion>Vitry-sur-Seine</wicri:noRegion></affiliation></author><author><name sortKey="Bordier, F" sort="Bordier, F" uniqKey="Bordier F" first="F" last="Bordier">F. Bordier</name></author><author><name sortKey="Dubedat, P" sort="Dubedat, P" uniqKey="Dubedat P" first="P" last="Dubédat">P. Dubédat</name></author><author><name sortKey="Peny, C" sort="Peny, C" uniqKey="Peny C" first="C" last="Pény">C. Pény</name></author><author><name sortKey="Imperato, A" sort="Imperato, A" uniqKey="Imperato A" first="A" last="Impérato">A. Impérato</name></author></analytic><series><title level="j">Neuroscience letters</title><idno type="ISSN">0304-3940</idno><imprint><date when="1997" type="published">1997</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>3,4-Dihydroxyphenylacetic Acid (metabolism)</term><term>Animals</term><term>Anti-Inflammatory Agents (pharmacology)</term><term>Corpus Striatum (drug effects)</term><term>Corpus Striatum (metabolism)</term><term>Disease Models, Animal</term><term>Dopamine (metabolism)</term><term>Dose-Response Relationship, Drug</term><term>Homovanillic Acid (metabolism)</term><term>Hypnotics and Sedatives (pharmacology)</term><term>Immunosuppressive Agents (pharmacology)</term><term>Male</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Parkinson Disease (metabolism)</term><term>Thalidomide (pharmacology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>3,4-Dihydroxyphenylacetic Acid</term><term>Dopamine</term><term>Homovanillic Acid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-Inflammatory Agents</term><term>Hypnotics and Sedatives</term><term>Immunosuppressive Agents</term><term>Thalidomide</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Corpus Striatum</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Corpus Striatum</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Dose-Response Relationship, Drug</term><term>Male</term><term>Mice</term><term>Mice, Inbred C57BL</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The effects of thalidomide, a sedative, anti-inflammatory and immunosuppressive agent were studied in the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) murine model of Parkinson's disease. The striatal levels of dopamine (DA) and of its main metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were measured both in the MPTP control group (3 x 15 mg/kg intraperitoneally) and in the thalidomide groups (repeated treatments at 25 mg/kg or 50 mg/kg postoperatively). For mice treated with thalidomide, a dose-dependent protection was observed against the MPTP-induced decrease in DA. The decrease in HVA levels was totally antagonized by thalidomide at both doses. That thalidomide has activity in this model suggests that an inflammatory process may be involved in the induction of lesions by MPTP in DAergic neurons.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9364513</PMID><DateCreated><Year>1998</Year><Month>01</Month><Day>15</Day></DateCreated><DateCompleted><Year>1998</Year><Month>01</Month><Day>15</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0304-3940</ISSN><JournalIssue CitedMedium="Print"><Volume>234</Volume><Issue>2-3</Issue><PubDate><Year>1997</Year><Month>Oct</Month><Day>03</Day></PubDate></JournalIssue><Title>Neuroscience letters</Title><ISOAbbreviation>Neurosci. Lett.</ISOAbbreviation></Journal><ArticleTitle>Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice.</ArticleTitle><Pagination><MedlinePgn>123-6</MedlinePgn></Pagination><Abstract><AbstractText>The effects of thalidomide, a sedative, anti-inflammatory and immunosuppressive agent were studied in the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) murine model of Parkinson's disease. The striatal levels of dopamine (DA) and of its main metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were measured both in the MPTP control group (3 x 15 mg/kg intraperitoneally) and in the thalidomide groups (repeated treatments at 25 mg/kg or 50 mg/kg postoperatively). For mice treated with thalidomide, a dose-dependent protection was observed against the MPTP-induced decrease in DA. The decrease in HVA levels was totally antagonized by thalidomide at both doses. That thalidomide has activity in this model suggests that an inflammatory process may be involved in the induction of lesions by MPTP in DAergic neurons.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boireau</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rhône-Poulenc Rorer S.A., Centre de Recherche de Vitry-Alfortville, Vitry-sur-Seine, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bordier</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Dubédat</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Pény</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Impérato</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Neurosci Lett</MedlineTA><NlmUniqueID>7600130</NlmUniqueID><ISSNLinking>0304-3940</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006993">Hypnotics and Sedatives</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>102-32-9</RegistryNumber><NameOfSubstance UI="D015102">3,4-Dihydroxyphenylacetic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>4Z8R6ORS6L</RegistryNumber><NameOfSubstance UI="D013792">Thalidomide</NameOfSubstance></Chemical><Chemical><RegistryNumber>9P21XSP91P</RegistryNumber><NameOfSubstance UI="D015632">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>X77S6GMS36</RegistryNumber><NameOfSubstance UI="D006719">Homovanillic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015632" MajorTopicYN="N">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015102" MajorTopicYN="N">3,4-Dihydroxyphenylacetic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006719" MajorTopicYN="N">Homovanillic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006993" MajorTopicYN="N">Hypnotics and Sedatives</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013792" MajorTopicYN="N">Thalidomide</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1997</Year><Month>11</Month><Day>19</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>11</Month><Day>19</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9364513</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country></list><tree><noCountry><name sortKey="Bordier, F" sort="Bordier, F" uniqKey="Bordier F" first="F" last="Bordier">F. Bordier</name><name sortKey="Dubedat, P" sort="Dubedat, P" uniqKey="Dubedat P" first="P" last="Dubédat">P. Dubédat</name><name sortKey="Imperato, A" sort="Imperato, A" uniqKey="Imperato A" first="A" last="Impérato">A. Impérato</name><name sortKey="Peny, C" sort="Peny, C" uniqKey="Peny C" first="C" last="Pény">C. Pény</name></noCountry><country name="France"><noRegion><name sortKey="Boireau, A" sort="Boireau, A" uniqKey="Boireau A" first="A" last="Boireau">A. Boireau</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001374 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001374 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:9364513
|texte= Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:9364513" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |